PROFILPELAJAR.COM

Gumarontinib

Gumarontinib
Clinical data
Other namesGlumetinib; SCC244; SC-C244
Routes of
administration		Oral
Legal status
Legal status
  • Rx in China
Identifiers
  • 6-(1-Methylpyrazol-4-yl)-1-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]sulfonylpyrazolo[4,3-b]pyridine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H17N9O2S
Molar mass459.49 g·mol−1
3D model (JSmol)
  • CN1C=C(C=N1)C2=CN3C(=NC=C3S(=O)(=O)N4C5=C(C=N4)N=CC(=C5)C6=CN(N=C6)C)C=C2
  • InChI=1S/C21H17N9O2S/c1-27-11-16(7-24-27)14-3-4-20-23-10-21(29(20)13-14)33(31,32)30-19-5-15(6-22-18(19)9-26-30)17-8-25-28(2)12-17/h3-13H,1-2H3
  • Key:RYBLECYFLJXEJX-UHFFFAOYSA-N

Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.[1]

Gumarontinib is a selective MET—hepatocyte growth factor receptor—inhibitor.[2]

References

  1. ^ "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". ecancer.org. 10 March 2023.
  2. ^ Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, et al. (May 2023). "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine. 59 101952. doi:10.1016/j.eclinm.2023.101952. PMC 10121392. PMID 37096188.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.